ClinicalTrials.gg
CompletedNCT04680273Updated Feb 2, 2023Results posted

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential

A Phase 1 interventional study of [14C]-GDC-9545 and GDC-9545 Solution for Infusion in Healthy Volunteers, sponsored by Genentech, Inc.. Completed at 1 site in United Kingdom. Open to female participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
Female
01

Study summary

This is an open-label, single-center, two part study in healthy female subjects of non-childbearing potential to investigate the absorption, metabolism, and excretion of [14C]-GDC-9545 (Part 1), the absolute bioavailability of formulations F12 and F18 (i.e., GDC-9545/F12 capsule, 30 mg and GDC-9545/F18 capsule, 30 mg) and relative bioavailability of GDC-9545 oral capsule F18 to the F12 formulation (Part 2). It is planned that Part 1 will begin prior to Part 2 of the study, and that the two parts of the study will partially overlap.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female subjects of non- that are non-pregnant, non-lactating females, who are either or surgically sterile, aged 30 to 65 years, inclusive, at time of signing the Form (ICF)
  • A (BMI) between 18.5 and 32.0 kg/m\^2, inclusive, at screening
  • Ability to comply with the study protocol
  • Must have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per day) (Part 1 only)

Exclusion criteria

Exclusion Criteria:

  • Women of , women who are pregnant or breastfeeding
  • Subjects who have received any medicinal product (IMP) in a clinical research study within the 90 days prior to Day 1 (Part 1) or Day 1 of Period 1 (Part 2)
  • History of serious adverse reaction or serious to any drug or allergy to the study drug formulation
  • Subjects who are, or are immediate family members of, a study site or Sponsor employee
  • Subjects who have previously been administered IMP in this study. Subjects who have taken part in Part 1 are not permitted to take part in Part 2.
  • Evidence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; i.e., the virus that causes COVID-19) infection
  • Positive for virus (HCV) antibody, surface antigen (HBsAg), or (HIV) antibody at screening
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption >14 units per week
  • A confirmed positive alcohol breath test at screening or admission
  • Current smokers and those who have smoked within the last 12 months
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  • Confirmed positive drugs of abuse test result at screening or admission
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study (Part 1 only)
  • Subjects who do not have suitable veins for multiple venipunctures/cannulation as assessed by the Investigator or delegate at screening
  • abnormal clinical chemistry, hematology, coagulation or urinalysis as judged by the Investigator
  • Evidence of renal impairment at screening, as indicated by an estimated (CLcr) of \<70 mL/min using the Cockcroft-Gault equation
  • History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal (GI) disease (especially peptic ulceration, GI bleeding, ulcerative colitis, Crohn's Disease or Irritable Bowel Syndrome), neurological or psychiatric disorder, as judged by the Investigator
  • Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator
  • Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
  • Subjects who are taking, or have taken, any medication (e.g., prescription drugs, over-the-counter drugs, hormone replacement therapy [HRT], vaccines, topical medications, herbal or homeopathic remedies, nutritional supplements), other than up to 4 g of paracetamol per day, in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the Investigator.
  • Subjects who are taking, or have taken, oral antibiotics within 4 weeks or IV antibiotics within 8 weeks prior to admission
  • Subjects who are taking, or have taken, any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to admission
  • History of GI surgery (with the exception of appendectomy unless it was performed within the previous 12 months) (Part 1 only)
  • Acute diarrhea or constipation in the 7 days before the predicted Day 1. If screening occurs >7 days before the Day 1, this criterion will be determined on Day 1. Diarrhea will be defined as the passage of liquid feces and/or a stool frequency of greater than 3 times per day. Constipation will be defined as a failure to open the bowels for 3 days (Part 1 only)
  • Malabsorption syndrome or other condition that would interfere with enteral absorption
  • History or presence of an abnormal that is clinically significant in the Investigator's opinion, including complete left bundle branch block, second- or third-degree atrioventricular heart block, or evidence of prior myocardial infarction
  • corrected through use of Fridericia's formula (QTcF) >440 msec demonstrated by at least two ECGs >30 minutes apart
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome
  • Confirmed (e.g., 2 consecutive measurements) baseline heart rate ≤50 bpm prior to enrollment
  • Current treatment with medications that are well known to prolong the QT interval
  • \<1.3 x 10\^9/L (1300/μL)
  • Failure to satisfy the Investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Part 1: [14C]-GDC-9545

    Participants will be enrolled to receive a single dose of Carbon-14 labelled \[14C\]-GDC-9545.

    Drug: [14C]-GDC-9545

  • Experimental
    Part 2: GDC-9545 Treatment Sequence BCD

    Participants will be randomly allocated to one of two treatment sequences (BCD for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.

    Drug: GDC-9545 Solution for Infusion · Drug: GDC-9545/F12 Capsule · Drug: GDC-9545/F18 Capsule

  • Experimental
    Part 2: GDC-9545 Treatment Sequence BDC

    Participants will be randomly allocated to one of two treatment sequences (BDC for this arm). In each treatment period, participants will receive a single dose of GDC-9545 in the fasted state in each of three treatment periods. The three treatment periods will be separated by a treatment-free washout between each study drug administration.

    Drug: GDC-9545 Solution for Infusion · Drug: GDC-9545/F12 Capsule · Drug: GDC-9545/F18 Capsule

Interventions

  • Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.

    Also known as: Giredestrant, RO7197597, RG6171

  • Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.

    Also known as: Giredestrant, RO7197597, RG6171

  • DrugGDC-9545/F12 Capsule

    Drug page: Giredestrant

    Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.

    Also known as: Giredestrant, RO7197597, RG6171

  • DrugGDC-9545/F18 Capsule

    Drug page: Giredestrant

    Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.

    Also known as: Giredestrant, RO7197597, RG6171

06

What researchers measure

Primary outcomes

  1. Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period

    Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

    Time frame: From Day 1 to Day 42 (0-1008 hours)

  2. Part 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period

    Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

    Time frame: From Day 1 to Day 42 (0-1008 hours)

  3. Part 1: Mean Amount of Total Radioactivity (Ae) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) by Collection Interval

    Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

    Time frame: 0-12, 12-24, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384, 384-408, 408-432, 432-456, 456-480, 480-648, 648-672, 672-816, 816-840, 840-984, & 984-1008 hours

  4. Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) by Cumulative Collection Interval

    Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

    Time frame: 0-24, 0-48, 0-72, 0-96, 0-120, 0-144, 0-168, 0-192, 0-216, 0-240, 0-264, 0-288, 0-312, 0-336, 0-360, 0-384, 0-408, 0-432, 0-456, 0-480, 0-648, 0-672, 0-816, 0-840, 0-984, and 0-1008 hours

  5. Part 1: Mean Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (Fe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) by Collection Interval

    Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

    Time frame: 0-12, 12-24, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384, 384-408, 408-432, 432-456, 456-480, 480-648, 648-672, 672-816, 816-840, 840-984, & 984-1008 hours

  6. Part 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) by Cumulative Collection Interval

    Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

    Time frame: 0-24, 0-48, 0-72, 0-96, 0-120, 0-144, 0-168, 0-192, 0-216, 0-240, 0-264, 0-288, 0-312, 0-336, 0-360, 0-384, 0-408, 0-432, 0-456, 0-480, 0-648, 0-672, 0-816, 0-840, 0-984, and 0-1008 hours

  7. Part 1: Maximum Observed Concentration (Cmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. The unit of measure for the total radioactivity concentrations is nanogram equivalent of free drug per millilitre.

    Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42

  8. Part 1: Time to Maximum Observed Concentration (Tmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42

  9. Part 1: Area Under the Concentration-Time Curve From Time 0 to 72 Hours [AUC(0-72)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: Pre-dose and post-dose at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, and 72 hours

  10. Part 1: Area Under the Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration [AUC(0-t)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42

  11. Part 1: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity (TR) concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42

  12. Part 1: Terminal Elimination Half-Life (t1/2), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity (TR) concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42

  13. Part 1: First Order Rate Constant Associated With Terminal Portion of the Curve (λz), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42

  14. Part 1: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F), Estimated for GDC-9545 in Plasma

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42

  15. Part 1: Apparent Volume of Distribution Where Fraction of Dose Bioavailable is Unknown (Vz/F), Estimated for GDC-9545 in Plasma

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

    Time frame: Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42

  16. Part 1: Total Radioactivity Concentrations of [14C]-GDC-9545 in Plasma and Whole Blood at Specified Timepoints

    Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. For calculation of the geometric mean, values reported as not detectable have been set to 0.5× the limit of detection (LOD); the LOD was 11.0 nanogram equivalent of free drug per millilitre (mL).

    Time frame: Postdose at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours

  17. Part 1: Whole Blood to Plasma Total Radioactivity Concentration Ratios of [14C]-GDC-9545 at Specified Timepoints

    Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. The limit of detection was 11.0 nanogram equivalent of free drug per millilitre (mL).

    Time frame: Postdose at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours

  18. Part 2: Absolute Bioavailability (F) of GDC-9545/F12 and /F18 Capsules Calculated Relative to GDC-9545 Solution for Infusion Based on the Adjusted AUC(0-∞), Estimated in Plasma Samples

    Absolute bioavailability of the GDC-9545/F12 and /F18 capsules were calculated relative to GDC-9545 solution for infusion based on the adjusted geometric mean AUC(0-∞) values obtained after oral and intravenous (IV) administration of GDC-9545. Log-transformed AUC(0-∞) was analyzed using mixed effects modelling techniques. The model included terms for treatment and sequence fitted as fixed effects and subject within sequence fitted as a random effect.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  19. Part 2: Relative Bioavailability Based on the Adjusted Cmax (Frel Cmax) of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples

    Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean Cmax values. Log-transformed Cmax was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  20. Part 2: Relative Bioavailability Based on the Adjusted AUC(0-∞) [Frel AUC(0-∞)] of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples

    Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean AUC(0-∞) values. Log-transformed AUC(0-∞) was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  21. Part 2: Relative Bioavailability Based on the Adjusted AUC(0-t) [Frel AUC(0-t)] of GDC-9545/F18 Capsule Calculated Relative to GDC-9545/F12 Capsule, Estimated in Plasma Samples

    Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean AUC(0-t) values. Log-transformed AUC(0-t) was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

Secondary outcomes

  1. Part 2: Cmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  2. Part 2: Tmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  3. Part 2: AUC(0-t) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  4. Part 2: AUC(0-∞) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  5. Part 2: t1/2 for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  6. Part 2: First Order Rate Constant Associated With Terminal Portion of the Curve (λz) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  7. Part 2: Total Body Clearance (CL) After a Single IV Administration for GDC-9545 Solution for Infusion, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  8. Part 2: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  9. Part 2: Volume of Distribution Based on the Terminal Phase Calculated Using AUC(0-∞) After a Single IV Administration (Vz) for GDC-9545 Solution for Infusion, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  10. Part 2: Apparent Volume of Distribution Based on the Terminal Phase Calculated With AUC(0-∞) After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (Vz/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

    Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

    Time frame: For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8

  11. Parts 1 and 2: Number of Participants With at Least One Adverse Event, With Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

    All adverse events (AEs) were recorded and the investigator independently assessed the seriousness and severity of each AE. AE severity was graded on a scale from 1 to 5 using the NCI-CTCAE v5.0; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening; and Grade 5 is death related to an AE. AEs of special interest were: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Cases of potential drug-induced kidney injury; Grade ≥3 nausea/vomiting/diarrhea; Grade ≥2 thromboembolic events; Grade ≥3 renal failure; Grade ≥3 hepatitis or elevation in ALT or AST; Grade ≥2 vaginal or uterine hemorrhage; Grade ≥2 bradycardia; Any grade of endometrial cancer; and, Suspected transmission of an infectious agent by the study drug.

    Time frame: From Baseline until end of study (up to 42 days and 35 days for Parts 1 and 2, respectively)

  12. Parts 1 and 2: Number of Participants With at Least One Abnormality in Laboratory Safety Tests, Reported as Adverse Events

    Participants provided blood samples at the specified timepoints for laboratory analysis of clinical chemistry, hematology, and coagulation panels (please refer to Appendices 1 and 2 of the protocol for a complete list). Any of the laboratory test results that were outside of a parameter's normal reference range were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

    Time frame: Part 1: Baseline and Discharge Day (up to 21 days); Part 2: Baseline, Day -1 of each of the 3 treatment periods, and Discharge Day (up to 29 days)

  13. Parts 1 and 2: Number of Participants With at Least One Abnormality in Vital Sign Measurements, Reported as Adverse Events

    Vital sign measurements included pulse rate, systolic and diastolic blood pressure while the participant was in a supine position for 5 minutes, and oral temperature. Any of the vital sign results that were outside of a parameter's normal range were considered abnormalities. Not every vital sign abnormality qualified as an adverse event (AE). A vital sign result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

    Time frame: Part 1: Baseline, predose and 1, 4, and 24 hours postdose, and Discharge Day (up to 21 days); Part 2: Baseline, predose and 0.5, 1, 4, and 24 hours postdose for each of the 3 treatment periods, and Discharge Day (up to 29 days)

  14. Parts 1 and 2: Number of Participants With at Least One Abnormality in 12-Lead Electrocardiogram Measurements, Reported as Adverse Events

    The 12-lead electrocardiograms (ECG) recorded measurements of heart rate, and PR, RR, QRS, uncorrected QT, and QTcF intervals. Any of the ECG parameter results that were outside of the normal range were considered abnormalities. Not every ECG abnormality qualified as an adverse event (AE). An ECG result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

    Time frame: Part 1: Baseline (Day 1, predose), 1, 4, and 24 hours postdose, and Discharge Day (up to 21 days); Part 2: Baseline (Day 1, predose), 0.5, 1, 4, and 24 hours postdose for each of the 3 treatment periods, and Discharge Day (up to 29 days)

07

Results

Posted Feb 2, 2023

Participant flow

Participant flow — Overall Study
MilestonePart 1: [14C]-GDC-9545Part 2: GDC-9545 Treatment Sequence BCDPart 2: GDC-9545 Treatment Sequence BDC
Started655
Part 1: received the planned dose of study drug600
Part 2: received all 3 planned doses of study drug055
Completed655
Not completed000

Outcome measures

PrimaryPart 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period

Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

Time frame:
From Day 1 to Day 42 (0-1008 hours)
Reported as:
Mean · milligram equivalent of free drug
Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period
milligram equivalent of free drugPart 1: [14C]-GDC-9545 - UrinePart 1: [14C]-GDC-9545 - FecesPart 1: [14C]-GDC-9545 - Total (Urine and Feces)
Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period2.78 ± 0.50320.70 ± 0.71223.50 ± 0.952
PrimaryPart 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period

Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

Time frame:
From Day 1 to Day 42 (0-1008 hours)
Reported as:
Mean · Percentage of radioactive dose
Part 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period
Percentage of radioactive dosePart 1: [14C]-GDC-9545 - UrinePart 1: [14C]-GDC-9545 - FecesPart 1: [14C]-GDC-9545 - Total (Urine and Feces)
Part 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection Period9.039 ± 1.63467.410 ± 2.31377.012 ± 2.794
PrimaryPart 1: Mean Amount of Total Radioactivity (Ae) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) by Collection Interval

Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

Time frame:
0-12, 12-24, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384, 384-408, 408-432, 432-456, 456-480, 480-648, 648-672, 672-816, 816-840, 840-984, & 984-1008 hours
Reported as:
Mean · nanogram equivalent of free drug
Part 1: Mean Amount of Total Radioactivity (Ae) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) by Collection Interval
nanogram equivalent of free drugPart 1: [14C]-GDC-9545 - UrinePart 1: [14C]-GDC-9545 - FecesPart 1: [14C]-GDC-9545 - Total (Urine and Feces)
0-12 hours668000 ± 78600——
12-24 hours307000 ± 54300——
0-24 hours—6980 ± 17100982000 ± 140000
24-48 hours410000 ± 564001980000 ± 32400002390000 ± 3250000
48-72 hours242000 ± 506003880000 ± 42300004120000 ± 4200000
72-96 hours174000 ± 548005730000 ± 44200005900000 ± 4380000
96-120 hours129000 ± 48000902000 ± 7460001030000 ± 761000
120-144 hours94100 ± 411002330000 ± 25900002420000 ± 2620000
144-168 hours56100 ± 220001180000 ± 8940001240000 ± 905000
168-192 hours54300 ± 20300453000 ± 357000507000 ± 352000
192-216 hours49900 ± 21900438000 ± 596000488000 ± 603000
216-240 hours27700 ± 13600732000 ± 1010000760000 ± 1020000
240-264 hours35300 ± 13300424000 ± 349000459000 ± 358000
264-288 hours30000 ± 9410470000 ± 633000500000 ± 639000
288-312 hours27800 ± 9520198000 ± 178000226000 ± 187000
312-336 hours23200 ± 5850188000 ± 159000211000 ± 162000
336-360 hours25200 ± 416063700 ± 6600088800 ± 67100
360-384 hours20300 ± 5510159000 ± 68800179000 ± 70700
384-408 hours17600 ± 3550122000 ± 95300139000 ± 96700
408-432 hours20800 ± 443069100 ± 5040089900 ± 51200
432-456 hours17300 ± 292073500 ± 5400090700 ± 55900
456-480 hours16300 ± 294082000 ± 4500098200 ± 46000
480-648 hours114000 ± 22100305000 ± 273000401000 ± 161000
648-672 hours16300 ± 382044300 ± 4860060600 ± 51700
672-816 hours93100 ± 19200362000 ± 296000493000 ± 267000
816-840 hours14700 ± 283088800 ± 70800104000 ± 72300
840-984 hours83900 ± 15500412000 ± 291000496000 ± 300000
984-1008 hours13300 ± 243048500 ± 3020061800 ± 32000
PrimaryPart 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) by Cumulative Collection Interval

Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

Time frame:
0-24, 0-48, 0-72, 0-96, 0-120, 0-144, 0-168, 0-192, 0-216, 0-240, 0-264, 0-288, 0-312, 0-336, 0-360, 0-384, 0-408, 0-432, 0-456, 0-480, 0-648, 0-672, 0-816, 0-840, 0-984, and 0-1008 hours
Reported as:
Mean · nanogram equivalent of free drug
Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) by Cumulative Collection Interval
nanogram equivalent of free drugPart 1: [14C]-GDC-9545 - UrinePart 1: [14C]-GDC-9545 - FecesPart 1: [14C]-GDC-9545 - Total (Urine and Feces)
0-24 hours975000 ± 1280006980 ± 17100982000 ± 140000
0-48 hours1380000 ± 1750001980000 ± 32300003370000 ± 3230000
0-72 hours1630000 ± 2150005860000 ± 48400007490000 ± 4750000
0-96 hours1800000 ± 26200011600000 ± 579000013400000 ± 5640000
0-120 hours1930000 ± 29900012500000 ± 552000014400000 ± 5330000
0-144 hours2020000 ± 33400014800000 ± 312000016800000 ± 2880000
0-168 hours2080000 ± 35200016000000 ± 274000018100000 ± 2510000
0-192 hours2130000 ± 37000016500000 ± 284000018600000 ± 2590000
0-216 hours2180000 ± 38900016900000 ± 265000019100000 ± 2380000
0-240 hours2210000 ± 40100017600000 ± 182000019800000 ± 1540000
0-264 hours2250000 ± 41300018100000 ± 162000020300000 ± 1340000
0-288 hours2280000 ± 42100018500000 ± 128000020800000 ± 1030000
0-312 hours2300000 ± 43000018700000 ± 116000021000000 ± 940000
0-336 hours2330000 ± 43600018900000 ± 111000021200000 ± 920000
0-360 hours2350000 ± 43900019000000 ± 112000021300000 ± 932000
0-384 hours2370000 ± 44500019100000 ± 111000021500000 ± 934000
0-408 hours2390000 ± 44800019300000 ± 106000021600000 ± 894000
0-432 hours2410000 ± 45100019300000 ± 107000021700000 ± 893000
0-456 hours2430000 ± 45400019400000 ± 103000021800000 ± 854000
0-480 hours2450000 ± 45600019500000 ± 105000021900000 ± 878000
0-648 hours2560000 ± 47300019800000 ± 101000022300000 ± 966000
0-672 hours2580000 ± 47500019800000 ± 96900022400000 ± 922000
0-816 hours2670000 ± 48800020200000 ± 74200022900000 ± 825000
0-840 hours2680000 ± 49000020300000 ± 73300023000000 ± 847000
0-984 hours2770000 ± 50100020700000 ± 71900023500000 ± 949000
0-1008 hours2780000 ± 50300020700000 ± 71200023500000 ± 952000
PrimaryPart 1: Mean Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (Fe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) by Collection Interval

Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

Time frame:
0-12, 12-24, 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264, 264-288, 288-312, 312-336, 336-360, 360-384, 384-408, 408-432, 432-456, 456-480, 480-648, 648-672, 672-816, 816-840, 840-984, & 984-1008 hours
Reported as:
Mean · Percentage of radioactive dose
Part 1: Mean Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (Fe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) by Collection Interval
Percentage of radioactive dosePart 1: [14C]-GDC-9545 - UrinePart 1: [14C]-GDC-9545 - FecesPart 1: [14C]-GDC-9545 - Total (Urine and Feces)
0-12 hours2.172 ± 0.255——
12-24 hours0.997 ± 0.176——
0-24 hours—0.023 ± 0.0563.191 ± 0.454
24-48 hours1.331 ± 0.1836.428 ± 10.5167.759 ± 10.575
48-72 hours0.787 ± 0.16412.603 ± 13.73513.390 ± 13.639
72-96 hours0.566 ± 0.17818.625 ± 14.35119.191 ± 14.234
96-120 hours0.420 ± 0.1562.932 ± 2.4233.352 ± 2.472
120-144 hours0.306 ± 0.1347.565 ± 8.4207.871 ± 8.510
144-168 hours0.182 ± 0.0723.848 ± 2.9054.030 ± 2.941
168-192 hours0.176 ± 0.0661.471 ± 1.1591.647 ± 1.145
192-216 hours0.162 ± 0.0711.424 ± 1.9371.586 ± 1.961
216-240 hours0.090 ± 0.0442.379 ± 3.2802.469 ± 3.319
240-264 hours0.115 ± 0.0431.377 ± 1.1341.492 ± 1.164
264-288 hours0.098 ± 0.0311.528 ± 2.0561.626 ± 2.077
288-312 hours0.090 ± 0.0310.644 ± 0.5800.734 ± 0.608
312-336 hours0.075 ± 0.0190.612 ± 0.5180.687 ± 0.527
336-360 hours0.082 ± 0.0140.207 ± 0.2140.289 ± 0.218
360-384 hours0.066 ± 0.0180.517 ± 0.2240.583 ± 0.230
384-408 hours0.057 ± 0.0120.396 ± 0.3100.453 ± 0.314
408-432 hours0.068 ± 0.0140.225 ± 0.1640.292 ± 0.166
432-456 hours0.056 ± 0.0090.239 ± 0.1750.295 ± 0.182
456-480 hours0.053 ± 0.0100.266 ± 0.1460.319 ± 0.150
480-648 hours0.371 ± 0.0720.993 ± 0.8891.808 ± 0.518
648-672 hours0.053 ± 0.0120.144 ± 0.1580.197 ± 0.168
672-816 hours0.303 ± 0.0621.178 ± 0.9631.601 ± 0.868
816-840 hours0.048 ± 0.0090.289 ± 0.2300.337 ± 0.235
840-984 hours0.273 ± 0.0501.339 ± 0.9451.612 ± 0.974
984-1008 hours0.043 ± 0.0080.158 ± 0.0980.201 ± 0.104
PrimaryPart 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) by Cumulative Collection Interval

Following a single oral dose of 30 milligrams of \[14C\]-GDC-9545, urine and fecal samples were collected over time from each participant. The amounts of total radioactivity excreted in the samples were determined using liquid scintillation counting. The lower limits of detection in urine and fecal samples were 0.423 and 8.36 nanogram equivalent of free drug per gram of sample, respectively. Following Day 21 (480 hours), where urine/fecal collections were no longer continuous and spot sampling days commenced, interpolation of Ae was calculated to estimate the amount excreted on non-collection days (collection intervals with interpolated values included 480-648 hours, 672-816 hours, and 840-984 hours).

Time frame:
0-24, 0-48, 0-72, 0-96, 0-120, 0-144, 0-168, 0-192, 0-216, 0-240, 0-264, 0-288, 0-312, 0-336, 0-360, 0-384, 0-408, 0-432, 0-456, 0-480, 0-648, 0-672, 0-816, 0-840, 0-984, and 0-1008 hours
Reported as:
Mean · Percentage of radioactive dose
Part 1: Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]-GDC-9545 Recovered in Urine, Feces, and Total (Urine and Feces Combined) by Cumulative Collection Interval
Percentage of radioactive dosePart 1: [14C]-GDC-9545 - UrinePart 1: [14C]-GDC-9545 - FecesPart 1: [14C]-GDC-9545 - Total (Urine and Feces)
0-24 hours3.169 ± 0.4150.023 ± 0.0563.191 ± 0.454
0-48 hours4.500 ± 0.5706.451 ± 10.50010.950 ± 10.498
0-72 hours5.286 ± 0.70019.054 ± 15.71824.340 ± 15.443
0-96 hours5.853 ± 0.85037.679 ± 18.82143.532 ± 18.320
0-120 hours6.272 ± 0.97340.611 ± 17.94146.884 ± 17.339
0-144 hours6.578 ± 1.08648.176 ± 10.14554.755 ± 9.345
0-168 hours6.761 ± 1.14452.024 ± 8.91958.785 ± 8.143
0-192 hours6.937 ± 1.20353.495 ± 9.23160.432 ± 8.410
0-216 hours7.099 ± 1.26454.919 ± 8.62962.018 ± 7.723
0-240 hours7.189 ± 1.30357.298 ± 5.92264.487 ± 4.999
0-264 hours7.304 ± 1.34358.676 ± 5.26965.979 ± 4.345
0-288 hours7.401 ± 1.36960.204 ± 4.17667.605 ± 3.358
0-312 hours7.492 ± 1.39960.848 ± 3.78468.339 ± 3.055
0-336 hours7.567 ± 1.41661.459 ± 3.61569.026 ± 2.990
0-360 hours7.649 ± 1.42861.666 ± 3.64569.315 ± 3.029
0-384 hours7.715 ± 1.44562.183 ± 3.62369.898 ± 3.035
0-408 hours7.772 ± 1.45562.579 ± 3.45370.351 ± 2.905
0-432 hours7.839 ± 1.46762.804 ± 3.46370.643 ± 2.903
0-456 hours7.895 ± 1.47563.043 ± 3.34670.938 ± 2.774
0-480 hours7.948 ± 1.48363.309 ± 3.40871.257 ± 2.853
0-648 hours8.319 ± 1.53664.302 ± 3.28573.065 ± 2.673
0-672 hours8.372 ± 1.54364.446 ± 3.15073.262 ± 2.540
0-816 hours8.675 ± 1.58565.624 ± 2.41274.863 ± 2.281
0-840 hours8.723 ± 1.59265.913 ± 2.38375.200 ± 2.365
0-984 hours8.995 ± 1.62967.252 ± 2.33676.812 ± 2.771
0-1008 hours9.039 ± 1.63467.410 ± 2.31377.012 ± 2.794
PrimaryPart 1: Maximum Observed Concentration (Cmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. The unit of measure for the total radioactivity concentrations is nanogram equivalent of free drug per millilitre.

Time frame:
Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
Part 1: Maximum Observed Concentration (Cmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
nanogram per millilitre (ng/mL)Part 1: [14C]-GDC-9545 - GDC-9545 in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood
Part 1: Maximum Observed Concentration (Cmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood74.3 ± 31.2124 ± 21.488.0 ± 25.8
PrimaryPart 1: Time to Maximum Observed Concentration (Tmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

Time frame:
Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Reported as:
Median · Hours
Part 1: Time to Maximum Observed Concentration (Tmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
HoursPart 1: [14C]-GDC-9545 - GDC-9545 in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood
Part 1: Time to Maximum Observed Concentration (Tmax), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood3.50 (2.00 to 5.00)5.00 (2.00 to 5.00)5.00 (2.50 to 5.00)
PrimaryPart 1: Area Under the Concentration-Time Curve From Time 0 to 72 Hours [AUC(0-72)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

Time frame:
Pre-dose and post-dose at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, and 72 hours
Reported as:
Geometric mean · nanogram*hours per milliltre (ng*h/mL)
Part 1: Area Under the Concentration-Time Curve From Time 0 to 72 Hours [AUC(0-72)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
nanogram*hours per milliltre (ng*h/mL)Part 1: [14C]-GDC-9545 - GDC-9545 in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood
Part 1: Area Under the Concentration-Time Curve From Time 0 to 72 Hours [AUC(0-72)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood1930 ± 32.23370 ± 24.42530 ± 22.5
Statistical analysis
  • Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma vs Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma · Geometric mean ratio: 0.573The geometric coefficient of variation (%) for the AUC(0-72) geometric mean ratio was 10.4%. The standard deviation (SD) reported is a geometric SD.
  • Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma vs Part 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood · Geometric mean ratio: 0.752The geometric coefficient of variation (%) for the AUC(0-72) geometric mean ratio was 3.5%. The standard deviation (SD) reported is a geometric SD.
PrimaryPart 1: Area Under the Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration [AUC(0-t)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

Time frame:
Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Reported as:
Geometric mean · nanogram*hours per milliltre (ng*h/mL)
Part 1: Area Under the Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration [AUC(0-t)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
nanogram*hours per milliltre (ng*h/mL)Part 1: [14C]-GDC-9545 - GDC-9545 in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood
Part 1: Area Under the Concentration-Time Curve From Time 0 to the Time of Last Measurable Concentration [AUC(0-t)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood2600 ± 43.84160 ± 40.33280 ± 40.9
Statistical analysis
  • Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma vs Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma · Geometric mean ratio: 0.625The geometric coefficient of variation (%) for the AUC(0-t) geometric mean ratio was 12.7%. The standard deviation (SD) reported is a geometric SD.
  • Part 1: [14C]-GDC-9545 - Total Radioactivity in Plasma vs Part 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood · Geometric mean ratio: 0.790The geometric coefficient of variation (%) for the AUC(0-t) geometric mean ratio was 15.9%. The standard deviation (SD) reported is a geometric SD.
PrimaryPart 1: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity (TR) concentrations in plasma and whole blood were determined using liquid scintillation counting.

Time frame:
Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Reported as:
Geometric mean · nanogram*hours per milliltre (ng*h/mL)
Part 1: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma
nanogram*hours per milliltre (ng*h/mL)Part 1: [14C]-GDC-9545 - GDC-9545 in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in Plasma
Part 1: Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)], Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma2680 ± 43.26480 ± 39.2
PrimaryPart 1: Terminal Elimination Half-Life (t1/2), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity (TR) concentrations in plasma and whole blood were determined using liquid scintillation counting.

Time frame:
Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Reported as:
Geometric mean · Hours
Part 1: Terminal Elimination Half-Life (t1/2), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
HoursPart 1: [14C]-GDC-9545 - GDC-9545 in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood
Part 1: Terminal Elimination Half-Life (t1/2), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood42.6 ± 24.948.4 ± 29.450.8 ± 46.4
PrimaryPart 1: First Order Rate Constant Associated With Terminal Portion of the Curve (λz), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

Time frame:
Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Reported as:
Geometric mean · 1/Hours
Part 1: First Order Rate Constant Associated With Terminal Portion of the Curve (λz), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood
1/HoursPart 1: [14C]-GDC-9545 - GDC-9545 in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood
Part 1: First Order Rate Constant Associated With Terminal Portion of the Curve (λz), Estimated for GDC-9545 in Plasma and for Total Radioactivity in Plasma and Whole Blood0.0163 ± 24.90.0143 ± 29.40.0136 ± 46.4
PrimaryPart 1: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F), Estimated for GDC-9545 in Plasma

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

Time frame:
Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Reported as:
Geometric mean · Litres per hour (L/h)
Part 1: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F), Estimated for GDC-9545 in Plasma
Litres per hour (L/h)Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma
Part 1: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F), Estimated for GDC-9545 in Plasma11.5 ± 43.2
PrimaryPart 1: Apparent Volume of Distribution Where Fraction of Dose Bioavailable is Unknown (Vz/F), Estimated for GDC-9545 in Plasma

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry. Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting.

Time frame:
Pre-dose and 1, 1.5, 2, 2.5, 3, 5, 6, 8, and 12 hours post-dose on Day 1, daily from Day 2 to Day 21, and Days 28, 35, and 42
Reported as:
Geometric mean · Litres per hour (L/h)
Part 1: Apparent Volume of Distribution Where Fraction of Dose Bioavailable is Unknown (Vz/F), Estimated for GDC-9545 in Plasma
Litres per hour (L/h)Part 1: [14C]-GDC-9545 - GDC-9545 in Plasma
Part 1: Apparent Volume of Distribution Where Fraction of Dose Bioavailable is Unknown (Vz/F), Estimated for GDC-9545 in Plasma705 ± 20.6
PrimaryPart 1: Total Radioactivity Concentrations of [14C]-GDC-9545 in Plasma and Whole Blood at Specified Timepoints

Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. For calculation of the geometric mean, values reported as not detectable have been set to 0.5× the limit of detection (LOD); the LOD was 11.0 nanogram equivalent of free drug per millilitre (mL).

Time frame:
Postdose at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours
Reported as:
Geometric mean · nanogram equivalent of free drug/mL
Part 1: Total Radioactivity Concentrations of [14C]-GDC-9545 in Plasma and Whole Blood at Specified Timepoints
nanogram equivalent of free drug/mLPart 1: [14C]-GDC-9545 - Total Radioactivity in PlasmaPart 1: [14C]-GDC-9545 - Total Radioactivity in Whole Blood
1 Hour64.7 ± 42.148.4 ± 32.9
1.5 Hours88.1 ± 29.266.7 ± 24.8
2 Hours111 ± 25.374.3 ± 26.3
2.5 Hours105 ± 25.176.7 ± 27.2
3 Hours108 ± 25.576.3 ± 24.9
4 Hours101 ± 22.374.4 ± 21.9
5 Hours123 ± 21.385.9 ± 22.3
6 Hours105 ± 18.970.4 ± 19.5
8 Hours89.1 ± 23.664.8 ± 22.2
12 Hours66.6 ± 22.552.3 ± 20.8
24 Hours45.6 ± 24.436.0 ± 26.2
48 Hours34.5 ± 29.524.6 ± 26.3
72 Hours22.7 ± 31.018.7 ± 25.0
96 Hours16.1 ± 64.59.97 ± 74.9
120 Hours9.88 ± 74.711.5 ± 64.4
144 Hours7.91 ± 60.37.92 ± 61.0
168 Hours6.64 ± 46.07.44 ± 49.2
PrimaryPart 1: Whole Blood to Plasma Total Radioactivity Concentration Ratios of [14C]-GDC-9545 at Specified Timepoints

Total radioactivity concentrations in plasma and whole blood were determined using liquid scintillation counting. The limit of detection was 11.0 nanogram equivalent of free drug per millilitre (mL).

Time frame:
Postdose at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours
Reported as:
Geometric mean · Ratio of concentrations (unitless)
Part 1: Whole Blood to Plasma Total Radioactivity Concentration Ratios of [14C]-GDC-9545 at Specified Timepoints
Ratio of concentrations (unitless)Part 1: [14C]-GDC-9545
1 Hour0.747 ± 12.1
1.5 Hours0.758 ± 6.7
2 Hours0.673 ± 5.4
2.5 Hours0.732 ± 2.9
3 Hours0.704 ± 4.6
4 Hours0.738 ± 0.7
5 Hours0.700 ± 10.6
6 Hours0.672 ± 2.8
8 Hours0.728 ± 4.1
12 Hours0.786 ± 10.0
24 Hours0.789 ± 7.4
48 Hours0.713 ± 5.6
72 Hours0.825 ± 7.6
96 Hours0.757 ± 2.0
120 Hours1.00 ± 30.7
144 Hours1.02 ± 27.5
168 Hours0.843 ± NA
PrimaryPart 2: Absolute Bioavailability (F) of GDC-9545/F12 and /F18 Capsules Calculated Relative to GDC-9545 Solution for Infusion Based on the Adjusted AUC(0-∞), Estimated in Plasma Samples

Absolute bioavailability of the GDC-9545/F12 and /F18 capsules were calculated relative to GDC-9545 solution for infusion based on the adjusted geometric mean AUC(0-∞) values obtained after oral and intravenous (IV) administration of GDC-9545. Log-transformed AUC(0-∞) was analyzed using mixed effects modelling techniques. The model included terms for treatment and sequence fitted as fixed effects and subject within sequence fitted as a random effect.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · Percentage
Part 2: Absolute Bioavailability (F) of GDC-9545/F12 and /F18 Capsules Calculated Relative to GDC-9545 Solution for Infusion Based on the Adjusted AUC(0-∞), Estimated in Plasma Samples
PercentagePart 2, PK: GDC-9545/F12 Capsule (Treatment C)Part 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: Absolute Bioavailability (F) of GDC-9545/F12 and /F18 Capsules Calculated Relative to GDC-9545 Solution for Infusion Based on the Adjusted AUC(0-∞), Estimated in Plasma Samples58.06 (53.45 to 63.07)58.70 (54.04 to 63.76)
PrimaryPart 2: Relative Bioavailability Based on the Adjusted Cmax (Frel Cmax) of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples

Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean Cmax values. Log-transformed Cmax was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · Percentage
Part 2: Relative Bioavailability Based on the Adjusted Cmax (Frel Cmax) of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples
PercentagePart 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: Relative Bioavailability Based on the Adjusted Cmax (Frel Cmax) of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples100.79 (93.87 to 108.22)
PrimaryPart 2: Relative Bioavailability Based on the Adjusted AUC(0-∞) [Frel AUC(0-∞)] of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples

Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean AUC(0-∞) values. Log-transformed AUC(0-∞) was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · Percentage
Part 2: Relative Bioavailability Based on the Adjusted AUC(0-∞) [Frel AUC(0-∞)] of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples
PercentagePart 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: Relative Bioavailability Based on the Adjusted AUC(0-∞) [Frel AUC(0-∞)] of the GDC-9545/F18 Capsule Calculated Relative to the GDC-9545/F12 Capsule, Estimated in Plasma Samples102.04 (98.96 to 105.22)
PrimaryPart 2: Relative Bioavailability Based on the Adjusted AUC(0-t) [Frel AUC(0-t)] of GDC-9545/F18 Capsule Calculated Relative to GDC-9545/F12 Capsule, Estimated in Plasma Samples

Relative bioavailability of the GDC-9545/F18 capsule was calculated relative to the GDC-9545/F12 capsule based on the adjusted geometric mean AUC(0-t) values. Log-transformed AUC(0-t) was analyzed using mixed effects modelling techniques. The model included terms for treatment, sequence, and period fitted as fixed effects and subject nested within sequence as a random effect.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · Percentage
Part 2: Relative Bioavailability Based on the Adjusted AUC(0-t) [Frel AUC(0-t)] of GDC-9545/F18 Capsule Calculated Relative to GDC-9545/F12 Capsule, Estimated in Plasma Samples
PercentagePart 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: Relative Bioavailability Based on the Adjusted AUC(0-t) [Frel AUC(0-t)] of GDC-9545/F18 Capsule Calculated Relative to GDC-9545/F12 Capsule, Estimated in Plasma Samples101.97 (98.44 to 105.62)
SecondaryPart 2: Cmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · ng/mL
Part 2: Cmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
ng/mLPart 2, PK: GDC-9545 Solution for Infusion (Treatment B)Part 2, PK: GDC-9545/F12 Capsule (Treatment C)Part 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: Cmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples804 ± 32.394.1 ± 23.193.8 ± 31.1
SecondaryPart 2: Tmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Median · hours
Part 2: Tmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
hoursPart 2, PK: GDC-9545 Solution for Infusion (Treatment B)Part 2, PK: GDC-9545/F12 Capsule (Treatment C)Part 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: Tmax for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples0.50 (0.25 to 0.60)5.00 (2.00 to 6.00)4.00 (2.00 to 5.00)
SecondaryPart 2: AUC(0-t) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · ng*h/mL
Part 2: AUC(0-t) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
ng*h/mLPart 2, PK: GDC-9545 Solution for Infusion (Treatment B)Part 2, PK: GDC-9545/F12 Capsule (Treatment C)Part 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: AUC(0-t) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples5700 ± 33.33120 ± 35.33150 ± 39.2
SecondaryPart 2: AUC(0-∞) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · ng*h/mL
Part 2: AUC(0-∞) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
ng*h/mLPart 2, PK: GDC-9545 Solution for Infusion (Treatment B)Part 2, PK: GDC-9545/F12 Capsule (Treatment C)Part 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: AUC(0-∞) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples5630 ± 32.53270 ± 38.33300 ± 42.2
SecondaryPart 2: t1/2 for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · hours
Part 2: t1/2 for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
hoursPart 2, PK: GDC-9545 Solution for Infusion (Treatment B)Part 2, PK: GDC-9545/F12 Capsule (Treatment C)Part 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: t1/2 for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples37.8 ± 33.935.2 ± 23.936.4 ± 21.6
SecondaryPart 2: First Order Rate Constant Associated With Terminal Portion of the Curve (λz) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · 1/Hours
Part 2: First Order Rate Constant Associated With Terminal Portion of the Curve (λz) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
1/HoursPart 2, PK: GDC-9545 Solution for Infusion (Treatment B)Part 2, PK: GDC-9545/F12 Capsule (Treatment C)Part 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: First Order Rate Constant Associated With Terminal Portion of the Curve (λz) for GDC-9545 Solution for Infusion and GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples0.0184 ± 33.90.0197 ± 23.90.0191 ± 21.6
SecondaryPart 2: Total Body Clearance (CL) After a Single IV Administration for GDC-9545 Solution for Infusion, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · Litres per hour (L/h)
Part 2: Total Body Clearance (CL) After a Single IV Administration for GDC-9545 Solution for Infusion, Estimated in Plasma Samples
Litres per hour (L/h)Part 2, PK: GDC-9545 Solution for Infusion (Treatment B)
Part 2: Total Body Clearance (CL) After a Single IV Administration for GDC-9545 Solution for Infusion, Estimated in Plasma Samples5.31 ± 32.6
SecondaryPart 2: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · Litres per hour (L/h)
Part 2: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Litres per hour (L/h)Part 2, PK: GDC-9545/F12 Capsule (Treatment C)Part 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: Total Body Clearance Calculated After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (CL/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples9.18 ± 38.39.08 ± 42.2
SecondaryPart 2: Volume of Distribution Based on the Terminal Phase Calculated Using AUC(0-∞) After a Single IV Administration (Vz) for GDC-9545 Solution for Infusion, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · Litres (L)
Part 2: Volume of Distribution Based on the Terminal Phase Calculated Using AUC(0-∞) After a Single IV Administration (Vz) for GDC-9545 Solution for Infusion, Estimated in Plasma Samples
Litres (L)Part 2, PK: GDC-9545 Solution for Infusion (Treatment B)
Part 2: Volume of Distribution Based on the Terminal Phase Calculated Using AUC(0-∞) After a Single IV Administration (Vz) for GDC-9545 Solution for Infusion, Estimated in Plasma Samples266 ± 21.5
SecondaryPart 2: Apparent Volume of Distribution Based on the Terminal Phase Calculated With AUC(0-∞) After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (Vz/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples

Pharmacokinetic parameters were estimated where possible and appropriate for each participant profile by non-compartmental analysis methods using Phoenix WinNonlin software. Plasma concentrations of GDC-9545 were determined using liquid chromatography with tandem mass spectrometry.

Time frame:
For each treatment period: Pre-dose and 0.25, 0.5, 0.58, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose on Day 1, and daily from Day 2 to Day 8
Reported as:
Geometric mean · Litres (L)
Part 2: Apparent Volume of Distribution Based on the Terminal Phase Calculated With AUC(0-∞) After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (Vz/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples
Litres (L)Part 2, PK: GDC-9545/F12 Capsule (Treatment C)Part 2, PK: GDC-9545/F18 Capsule (Treatment D)
Part 2: Apparent Volume of Distribution Based on the Terminal Phase Calculated With AUC(0-∞) After a Single Extravascular Administration Where Fraction of Dose Bioavailable is Unknown (Vz/F) for GDC-9545/F12 and /F18 Capsules, Estimated in Plasma Samples466 ± 20.0476 ± 24.5
SecondaryParts 1 and 2: Number of Participants With at Least One Adverse Event, With Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

All adverse events (AEs) were recorded and the investigator independently assessed the seriousness and severity of each AE. AE severity was graded on a scale from 1 to 5 using the NCI-CTCAE v5.0; any events not specifically listed in the scale were defined as: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe or medically significant; Grade 4 is life-threatening; and Grade 5 is death related to an AE. AEs of special interest were: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Cases of potential drug-induced kidney injury; Grade ≥3 nausea/vomiting/diarrhea; Grade ≥2 thromboembolic events; Grade ≥3 renal failure; Grade ≥3 hepatitis or elevation in ALT or AST; Grade ≥2 vaginal or uterine hemorrhage; Grade ≥2 bradycardia; Any grade of endometrial cancer; and, Suspected transmission of an infectious agent by the study drug.

Time frame:
From Baseline until end of study (up to 42 days and 35 days for Parts 1 and 2, respectively)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With at Least One Adverse Event, With Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
ParticipantsPart 1: [14C]-GDC-9545Part 2: GDC-9545 Solution for Infusion (Treatment B)Part 2: GDC-9545/F12 Capsule (Treatment C)Part 2: GDC-9545/F18 Capsule (Treatment D)Part 2: Overall: Any GDC-9545 (Treatments B, C, or D)
Any Adverse Event (AE)35349
Serious AE00000
Grade 1 AE34326
Grade 2 AE01023
Grade ≥3 AE00000
AE Related to Study Drug01113
AE Leading to Withdrawal of Study Drug00000
AE of Special Interest00000
SecondaryParts 1 and 2: Number of Participants With at Least One Abnormality in Laboratory Safety Tests, Reported as Adverse Events

Participants provided blood samples at the specified timepoints for laboratory analysis of clinical chemistry, hematology, and coagulation panels (please refer to Appendices 1 and 2 of the protocol for a complete list). Any of the laboratory test results that were outside of a parameter's normal reference range were considered abnormalities. Not every laboratory abnormality qualified as an adverse event (AE). A laboratory test result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

Time frame:
Part 1: Baseline and Discharge Day (up to 21 days); Part 2: Baseline, Day -1 of each of the 3 treatment periods, and Discharge Day (up to 29 days)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With at Least One Abnormality in Laboratory Safety Tests, Reported as Adverse Events
ParticipantsPart 1: [14C]-GDC-9545Part 2: GDC-9545 Solution for Infusion (Treatment B)Part 2: GDC-9545/F12 Capsule (Treatment C)Part 2: GDC-9545/F18 Capsule (Treatment D)
Parts 1 and 2: Number of Participants With at Least One Abnormality in Laboratory Safety Tests, Reported as Adverse Events0000
SecondaryParts 1 and 2: Number of Participants With at Least One Abnormality in Vital Sign Measurements, Reported as Adverse Events

Vital sign measurements included pulse rate, systolic and diastolic blood pressure while the participant was in a supine position for 5 minutes, and oral temperature. Any of the vital sign results that were outside of a parameter's normal range were considered abnormalities. Not every vital sign abnormality qualified as an adverse event (AE). A vital sign result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

Time frame:
Part 1: Baseline, predose and 1, 4, and 24 hours postdose, and Discharge Day (up to 21 days); Part 2: Baseline, predose and 0.5, 1, 4, and 24 hours postdose for each of the 3 treatment periods, and Discharge Day (up to 29 days)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With at Least One Abnormality in Vital Sign Measurements, Reported as Adverse Events
ParticipantsPart 1: [14C]-GDC-9545Part 2: GDC-9545 Solution for Infusion (Treatment B)Part 2: GDC-9545/F12 Capsule (Treatment C)Part 2: GDC-9545/F18 Capsule (Treatment D)
Parts 1 and 2: Number of Participants With at Least One Abnormality in Vital Sign Measurements, Reported as Adverse Events0000
SecondaryParts 1 and 2: Number of Participants With at Least One Abnormality in 12-Lead Electrocardiogram Measurements, Reported as Adverse Events

The 12-lead electrocardiograms (ECG) recorded measurements of heart rate, and PR, RR, QRS, uncorrected QT, and QTcF intervals. Any of the ECG parameter results that were outside of the normal range were considered abnormalities. Not every ECG abnormality qualified as an adverse event (AE). An ECG result was reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

Time frame:
Part 1: Baseline (Day 1, predose), 1, 4, and 24 hours postdose, and Discharge Day (up to 21 days); Part 2: Baseline (Day 1, predose), 0.5, 1, 4, and 24 hours postdose for each of the 3 treatment periods, and Discharge Day (up to 29 days)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With at Least One Abnormality in 12-Lead Electrocardiogram Measurements, Reported as Adverse Events
ParticipantsPart 1: [14C]-GDC-9545Part 2: GDC-9545 Solution for Infusion (Treatment B)Part 2: GDC-9545/F12 Capsule (Treatment C)Part 2: GDC-9545/F18 Capsule (Treatment D)
Parts 1 and 2: Number of Participants With at Least One Abnormality in 12-Lead Electrocardiogram Measurements, Reported as Adverse Events0000

Adverse events

Collected over From Baseline until end of study (up to 42 days and 35 days for Parts 1 and 2, respectively). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: [14C]-GDC-95450/6 (0%)0/6 (0%)3/6 (50%)
Part 2: GDC-9545 Solution for Infusion (Treatment B)0/10 (0%)0/10 (0%)5/10 (50%)
Part 2: GDC-9545/F12 Capsule (Treatment C)0/10 (0%)0/10 (0%)3/10 (30%)
Part 2: GDC-9545/F18 Capsule (Treatment D)0/10 (0%)0/10 (0%)4/10 (40%)
Part 2: Overall: Any GDC-9545 (Treatments B, C, or D)0/10 (0%)0/10 (0%)9/10 (90%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPart 1: [14C]-GDC-9545Part 2: GDC-9545 Solution for Infusion (Treatment B)Part 2: GDC-9545/F12 Capsule (Treatment C)Part 2: GDC-9545/F18 Capsule (Treatment D)Part 2: Overall: Any GDC-9545 (Treatments B, C, or D)
InsomniaPsychiatric disorders0/63/100/101/104/10
DiarrhoeaGastrointestinal disorders0/61/101/100/102/10
External ear painEar and labyrinth disorders1/60/100/100/100/10
Gastrooesophageal reflux diseaseGastrointestinal disorders1/60/100/100/100/10
Injection site painGeneral disorders1/60/100/100/100/10
Dermatitis atopicSkin and subcutaneous tissue disorders1/60/100/100/100/10
DyspepsiaGastrointestinal disorders0/60/101/101/101/10
FlatulenceGastrointestinal disorders0/60/101/100/101/10
ToothacheGastrointestinal disorders0/61/100/100/101/10
FatigueGeneral disorders0/60/101/100/101/10

Baseline characteristics

The overall number of baseline participants includes a total of 16 participants who were enrolled in either Part 1 (N = 6) or Part 2 (N = 10) of the study.

Age, Continuous
Age, Continuous(Years)Part 1: [14C]-GDC-9545Part 2: GDC-9545 Treatment Sequence BCDPart 2: GDC-9545 Treatment Sequence BDCTotal
Part 156.2 ± 3.5——56.2 ± 3.5
Part 2—58.8 ± 5.657.6 ± 3.058.2 ± 4.3
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: [14C]-GDC-9545Part 2: GDC-9545 Treatment Sequence BCDPart 2: GDC-9545 Treatment Sequence BDCTotal
Part 1 — Female6——6
Part 1 — Male0——0
Part 2 — Female—5510
Part 2 — Male—000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: [14C]-GDC-9545Part 2: GDC-9545 Treatment Sequence BCDPart 2: GDC-9545 Treatment Sequence BDCTotal
Part 1 — Hispanic or Latino0——0
Part 1 — Not Hispanic or Latino6——6
Part 1 — Unknown or Not Reported0——0
Part 2 — Hispanic or Latino—000
Part 2 — Not Hispanic or Latino—5510
Part 2 — Unknown or Not Reported—000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: [14C]-GDC-9545Part 2: GDC-9545 Treatment Sequence BCDPart 2: GDC-9545 Treatment Sequence BDCTotal
Part 1 — American Indian or Alaska Native0——0
Part 1 — Asian0——0
Part 1 — Native Hawaiian or Other Pacific Islander0——0
Part 1 — Black or African American0——0
Part 1 — White6——6
Part 1 — More than one race0——0
Part 1 — Unknown or Not Reported0——0
Part 2 — American Indian or Alaska Native—000
Part 2 — Asian—000
Part 2 — Native Hawaiian or Other Pacific Islander—000
Part 2 — Black or African American—000
Part 2 — White—5510
Part 2 — More than one race—000
Part 2 — Unknown or Not Reported—000
08

Study locations

1 site
  • Quotient Sciences
    Nottingham, NG11 6JS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Apr 2021, 3 months.

Results were first posted in Feb 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2020
First posted
Dec 22, 2020
StartActual
Jan 7, 2021
Primary completionActual
Apr 12, 2021
CompletionActual
Apr 12, 2021
Results first posted
Feb 2, 2023
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04680273
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 22, 2020
Start date
Jan 7, 2021
Primary completion
Apr 12, 2021
Completion
Apr 12, 2021
Results posted
Feb 2, 2023
Last update
Feb 2, 2023

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Giredestrant

Start the discussion